172 related articles for article (PubMed ID: 20589834)
1. Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.
Shen DW; Ma J; Okabe M; Zhang G; Xia D; Gottesman MM
J Cell Physiol; 2010 Nov; 225(3):822-8. PubMed ID: 20589834
[TBL] [Abstract][Full Text] [Related]
2. RAB8 enhances TMEM205-mediated cisplatin resistance.
Shen DW; Gottesman MM
Pharm Res; 2012 Mar; 29(3):643-50. PubMed ID: 21969054
[TBL] [Abstract][Full Text] [Related]
3. Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.
Shen DW; Liang XJ; Suzuki T; Gottesman MM
Mol Pharmacol; 2006 Apr; 69(4):1383-8. PubMed ID: 16394183
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
Calo CA; Smith BQ; Dorayappan KDP; Saini U; Lightfoot M; Wagner V; Kalaiyarasan D; Cosgrove C; Wang QE; Maxwell GL; Kálai T; Kuppusamy P; Cohn DE; Selvendiran K
Gynecol Oncol; 2022 Jan; 164(1):136-145. PubMed ID: 34756749
[TBL] [Abstract][Full Text] [Related]
5. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum.
Liang XJ; Shen DW; Chen KG; Wincovitch SM; Garfield SH; Gottesman MM
J Cell Physiol; 2005 Mar; 202(3):635-41. PubMed ID: 15546142
[TBL] [Abstract][Full Text] [Related]
6. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
7. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis.
Yamamoto K; Okamoto A; Isonishi S; Ochiai K; Ohtake Y
Biochem Biophys Res Commun; 2001 Feb; 280(4):1148-54. PubMed ID: 11162647
[TBL] [Abstract][Full Text] [Related]
8. Codominance of cisplatin resistance in somatic cell hybrids.
Ying YL; Shen DW; Liang XJ; Gottesman MM
J Cell Physiol; 2003 Jul; 196(1):63-9. PubMed ID: 12767041
[TBL] [Abstract][Full Text] [Related]
9. A recombinant platform to characterize the role of transmembrane protein hTMEM205 in Pt(II)-drug resistance and extrusion.
Gallenito MJ; Qasim TS; Tutol JN; Prakash V; Dodani SC; Meloni G
Metallomics; 2020 Oct; 12(10):1542-1554. PubMed ID: 32789331
[TBL] [Abstract][Full Text] [Related]
10. Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.
Saini U; Smith BQ; Dorayappan KDP; Yoo JY; Maxwell GL; Kaur B; Konishi I; O'Malley D; Cohn DE; Selvendiran K
J Ovarian Res; 2022 Dec; 15(1):130. PubMed ID: 36476493
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells.
Shen DW; Su A; Liang XJ; Pai-Panandiker A; Gottesman MM
Br J Cancer; 2004 Jul; 91(2):270-6. PubMed ID: 15199393
[TBL] [Abstract][Full Text] [Related]
12. Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells.
Zhu K; Chen L; Han X; Wang J; Wang J
Oncol Rep; 2012 Apr; 27(4):1027-34. PubMed ID: 22245869
[TBL] [Abstract][Full Text] [Related]
13. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism.
Liang XJ; Finkel T; Shen DW; Yin JJ; Aszalos A; Gottesman MM
Mol Cancer Res; 2008 Sep; 6(9):1499-506. PubMed ID: 18723829
[TBL] [Abstract][Full Text] [Related]
14. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
Shu XR; Wu J; Sun H; Chi LQ; Wang JH
Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
[TBL] [Abstract][Full Text] [Related]
15. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.
Xue X; You S; Zhang Q; Wu Y; Zou GZ; Wang PC; Zhao YL; Xu Y; Jia L; Zhang X; Liang XJ
Mol Pharm; 2012 Mar; 9(3):634-44. PubMed ID: 22289032
[TBL] [Abstract][Full Text] [Related]
16. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
[TBL] [Abstract][Full Text] [Related]
17. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
18. TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/β-catenin signaling pathway and promoting the epithelial mesenchymal transition.
Liu SL; Lin HX; Lin CY; Sun XQ; Ye LP; Qiu F; Wen W; Hua X; Wu XQ; Li J; Song LB; Guo L
Cancer Lett; 2017 Aug; 402():117-130. PubMed ID: 28583847
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.
Shen DW; Pouliot LM; Hall MD; Gottesman MM
Pharmacol Rev; 2012 Jul; 64(3):706-21. PubMed ID: 22659329
[TBL] [Abstract][Full Text] [Related]
20. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.
Barr MP; Gray SG; Hoffmann AC; Hilger RA; Thomale J; O'Flaherty JD; Fennell DA; Richard D; O'Leary JJ; O'Byrne KJ
PLoS One; 2013; 8(1):e54193. PubMed ID: 23349823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
